A novel acquired <em>EGFR-SEPT14</em> fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma

Weidong Wang; Wang Lv; Hui Wang; Yang Xu; Junrong Yan; Han-Ming Shen; Liqun Shan; Jian Hu

doi:10.1016/j.gendis.2023.02.019

您当前的位置：

首页 >

文章列表页 >

A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma

Rapid Communications | 更新时间：2024-02-04

- A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma
- A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma
- Genes & Diseases 2023年1卷第6期页码：2241-2244
- 作者机构：
  
  1. Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University,Zhejiang,Hangzhou,China,310003
  2. Faculty of Health Sciences, University of Macau, Macau SAR,China,519000
  3. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center,Guangdong,Guangzhou,China,510060
  4. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Guangdong,Guangzhou,China,510060
  5. Medical Department, Nanjing Geneseeq Technology Inc,Jiangsu,Nanjing,China,210000
  6. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore,Singapore,Singapore,119077
  7. Department of Thoracic Surgery, The First People's Hospital of Wenling, Wenling,Zhejiang,China,317599
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.02.019
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-11-1，
扫描看全文
A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma[J]. Genes & Diseases, 2023,1(6):2241-2244.

Weidong Wang, Wang Lv, Hui Wang, et al. A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma[J]. Genes & Diseases, 2023,1(6):2241-2244.
A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma[J]. Genes & Diseases, 2023,1(6):2241-2244. DOI： 10.1016/j.gendis.2023.02.019.

Weidong Wang, Wang Lv, Hui Wang, et al. A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma[J]. Genes & Diseases, 2023,1(6):2241-2244. DOI： 10.1016/j.gendis.2023.02.019.

摘要

Abstract

关键词

Keywords

references

1 K. Konduri, J.N. Gallant, Y.K. Chae, et al.EGFR fusions as novel therapeutic targets in lung cancer Cancer Discov, 6 (6) (2016), pp. 601-611

2 A. Zehir, R. Benayed, R.H. Shah, et al.Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients Nat Med, 23 (6) (2017), pp. 703-713

3 Y.C. Zhu, W.X. Wang, X.L. Li, et al.Identification of a novel icotinib-sensitive EGFR-SEPTIN14 fusion variant in lung adenocarcinoma by next-generation sequencing J Thorac Oncol, 14 (8) (2019), pp. e181-e183

4 H. Xu, C. ShaoKIF5B- EGFR fusion: a novel EGFR mutation in lung adenocarcinoma Onco Targets Ther, 13 (2020), pp. 8317-8321

5 V. Frattini, V. Trifonov, J.M. Chan, et al.The integrated landscape of driver genomic alterations in glioblastoma Nat Genet, 45 (10) (2013), pp. 1141-1149

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据

A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma

A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma

DOI：10.1016/j.gendis.2023.02.019

摘要

Abstract

关键词

Keywords

references